Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377

Type I Hypersensitivity

COMPLETED PHASE2

Phase 2 Study in Adults Sensitized to Short Ragweed

NCT00670384

Allergic Rhinitis

WITHDRAWN PHASE2

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

NCT05297760

Rhinitis, Allergic, Seasonal Rhinitis; Allergic, With Asthma Allergic Rhinitis +2 more

COMPLETED PHASE1/PHASE2

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

NCT01469182

Allergy

COMPLETED PHASE3

Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber

NCT06104293

Allergic Rhinitis Due to Grass Pollen

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To induce clinical tolerance, a failure to respond to an allergen to which one was previously responsive, is an important objective for physicians, one that plays a significant role in the primary prevention of allergic reactions in the clinical practice of Allergy \& Immunology. The tolerance resulting after standard subcutaneous immunotherapy to aeroallergen and insect venom allergens is long lasting and allergen-specific, and may involve antigen-specific T regulatory cells. In contrast, tolerance resulting from drug desensitization protocols is short-lived, and postulated to target mast cells and basophils. Research into the cellular and biochemical processes by which desensitization occurs has revealed that mast cells desensitized to one antigen in vitro, under certain conditions, lose the ability to degranulate to unrelated antigens or to direct FcεRI cross-linking. Preliminary data suggests that this cross-desensitization can happen in patients undergoing incremental desensitization, depending in part on the percentage of IgE targeted to the allergen used for desensitization. This proposal therefore aims to explore desensitization and cross-desensitization in human volunteers undergoing standard sublingual (SL) immunotherapy to grass or ragweed pollen.

Subjects will undergo SL immunotherapy with either Timothy or Short Ragweed tablets, taking one tablet per day, or will take a placebo tablet. Titration skin testing to Timothy or Short Ragweed, to one or preferably two additional allergens to which the subject is sensitive, and to codeine as a control for mast cell activation capability through a non-IgE-dependent pathway will be performed to determine the PC3 value (see below). Skin testing, including histamine and diluent controls, will be performed prior to and at one and four weeks after initiation of immunotherapy. At each time point, blood will be obtained to measure total and antigen-specific IgE levels, tryptase and cytokine levels, and basophil activation with the relevant allergens and C5a as a non-IgE-mediated control for basophil activation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunologic Desensitization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sublingual allergen tablets

Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.

Group Type EXPERIMENTAL

allergen extract tablet

Intervention Type DRUG

1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet

Placebo

Subjects will be administered placebo sublingual tablets

Group Type PLACEBO_COMPARATOR

Placebo tablet

Intervention Type DRUG

1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

allergen extract tablet

1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet

Intervention Type DRUG

Placebo tablet

1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ragwitek Grastek

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Verified allergic sensitivity to either Timothy Grass or Short Ragweed pollen (primary allergen)
* Verified allergic sensitivity to at least one allergen in addition to the primary allergen

Exclusion Criteria

* Negative skin testing to Timothy Grass or Short Ragweed pollen and at least one other environmental allergen
* Dermatographism
* Severe dermatologic condition that may interfere with skin testing
* Pregnancy
* H1 receptor antihistamine taken within 7 days of testing
* Systemic steroids
* Omalizumab taken at any time in the past
* Receiving or received allergen immunotherapy
* Desensitized to any drug within 6 months
* Current uncontrolled or severe asthma
* Eosinophilic esophagitis
* Significant pulmonary, cardiovascular, renal, hepatobiliary, or neurological diseases, or another disease process felt to put a subject at increased risk for adverse events
* Hypersensitivity to any of the inactive ingredients in the allergen extract tablets
* History of mental illness or drug or alcohol abuse that could interfere with the ability to comply with study requirements
* Inability or unwillingness to give written informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes